HB

Harvard Bioscience IncNASDAQ HBIO Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Nov, 2024

Last price

Market cap $B

0.118

Micro

Exchange

XNAS - Nasdaq

HBIO Stock Analysis

HB

Uncovered

Harvard Bioscience Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-8/100

Low score

Market cap $B

0.118

Dividend yield

Shares outstanding

42.19 B

Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The Company organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. It primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

View Section: Eyestock Rating